1. Medtech Insight
  2. >>Device Area
  3. >>Surgery

Johnson & Johnson Unveils Details On Ottava Soft-Tissue Robot, Chasing Intuitive, Medtronic

 
• By Marion Webb

J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.

Robots in medicine. Innovative medicine. Robotic surgery.

Johnson & Johnson (Pty) Ltd released details of its much-anticipated Ottava robotic surgery platform for soft-tissue procedures during the company’s virtual medical device update on 19 November.

The platform is slated to enter human clinical trials in the second half of 2022 with a possible launch expected...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Robotic Surgery

More from Surgery

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By Marion Webb

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.

Intuitive Surgical Sees Early Wins With Da Vinci 5, Lifts FY25 Guidance As Tariff Impact Eases

 
• By Shubham Singh

For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.

ForSight Sets Its Sights On Automating Delicate Eye Procedures

 
• By Marion Webb

ForSight Robotics is developing a robotic platform to automate cataract and other eye surgeries, aiming to ease surgeon strain and expand access. Backed by $200m in total funding, it's targeting a first human surgery using Oryom by year-end and is in discussions with US FDA.